Literature DB >> 24233154

Leser–Trélat syndrome in malignant mesothelioma and pulmonary adenocarcinoma: is the EGFR pathway part of the syndrome?

Rikke Karlin Jepsen, Anne Guldhammer Skov, Birgit Guldhammer Skov.   

Abstract

The syndrome of Leser–Trélat (LT) is characterized by the sudden appearance of multiple seborrhoeic keratoses (SKs) in association with internal occult malignancy. Usually, the syndrome has been associated with adenocarcinoma, most frequently of the gastrointestinal tract and breast. The pathogenesis is unclear but might be explained by circulating tumor-associated growth factors. We present two thoracic malignancies associated with LT: adenocarcinoma of the lung (ACL) and pleural malignant mesothelioma (MM). Both malignant tumors expressed high levels of epidermal growth factor receptors (EGFR) detected by immunohistochemistry (IHC), with membranous staining on the majority of malignant cells corresponding to maximum IHC scores of 290 and 300, respectively, for the MM and the ACL. SKs revealed a universal membranous staining throughout the entire epithelium with no difference in EGFR expression between the two cases and two controls with no malignant history. By fluorescence in situ hybridization, no amplification of the EGFR gene in malignant tumors as well as in SK lesions was observed. Further investigations are needed to see whether tumor-associated EGFR ligands/EGFR autocrine loops in malignant cells expressing high levels of EGFR protein on the surface might play a role for the development of SKs, as well as for the growth of malignant tumors in LT.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24233154     DOI: 10.1007/s00428-013-1503-4

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  12 in total

1.  Melanoma, growth factors, acanthosis nigricans, the sign of Leser-Trélat, and multiple acrochordons. A possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes.

Authors:  D L Ellis; S P Kafka; J C Chow; L B Nanney; W H Inman; M E McCadden; L E King
Journal:  N Engl J Med       Date:  1987-12-17       Impact factor: 91.245

2.  A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma.

Authors:  Yasunori Enomoto; Takahiko Kasai; Maiko Takeda; Masato Takano; Kouhei Morita; Eiji Kadota; Norishige Iizuka; Hiroshi Maruyama; Joji Haratake; Yu Kojima; Naoya Ikeda; Akitaka Nonomura
Journal:  Pathol Int       Date:  2012-01-30       Impact factor: 2.534

3.  EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

Authors:  Robert Pirker; Jose R Pereira; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Keunchil Park; Filippo de Marinis; Wilfried E E Eberhardt; Luis Paz-Ares; Stephan Störkel; Karl-Maria Schumacher; Anja von Heydebreck; Ilhan Celik; Kenneth J O'Byrne
Journal:  Lancet Oncol       Date:  2011-11-04       Impact factor: 41.316

4.  Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test.

Authors:  Josef Rüschoff; Keith M Kerr; Hans J Grote; Peter Middel; Anja von Heydebreck; Venâncio A Alves; Stephan E Baldus; Reinhard Büttner; Lina Carvalho; Ludger Fink; Wolfram Jochum; Anthony W I Lo; Fernando López-Ríos; Alexander Marx; Thierry J Molina; Włodzimierz T Olszewski; Ralf J Rieker; Marco Volante; Erik Thunnissen; Fritz Wrba; Ilhan Celik; Stephan Störkel
Journal:  Arch Pathol Lab Med       Date:  2012-12-27       Impact factor: 5.534

5.  Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations.

Authors:  Ottavio Rena; Luciano R Boldorini; Erica Gaudino; Caterina Casadio
Journal:  J Surg Oncol       Date:  2011-03-21       Impact factor: 3.454

6.  Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study.

Authors:  Hyun Ju Lee; Xianhua Xu; Gheeyoung Choe; Doo Hyun Chung; Jeong-Wook Seo; Jae Ho Lee; Choon-Taek Lee; Sanghoon Jheon; Sook-Whan Sung; Jin-Haeng Chung
Journal:  Lung Cancer       Date:  2009-08-26       Impact factor: 5.705

Review 7.  Epidermal manifestations of internal malignancy.

Authors:  Rachael L Moore; Theresa S Devere
Journal:  Dermatol Clin       Date:  2008-01       Impact factor: 3.478

Review 8.  Sign of Leser-Trélat.

Authors:  R A Schwartz
Journal:  J Am Acad Dermatol       Date:  1996-07       Impact factor: 11.527

9.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Authors:  Robert Pirker; Jose R Pereira; Aleksandra Szczesna; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Ihor Vynnychenko; Keunchil Park; Chih-Teng Yu; Valentyn Ganul; Jae-Kyung Roh; Emilio Bajetta; Kenneth O'Byrne; Filippo de Marinis; Wilfried Eberhardt; Thomas Goddemeier; Michael Emig; Ulrich Gatzemeier
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321

10.  Leser-Trélat syndrome in patients affected by six multiple metachronous primitive cancers.

Authors:  Giovanni Ponti; Gabriele Luppi; Lorena Losi; Alberto Giannetti; Stefania Seidenari
Journal:  J Hematol Oncol       Date:  2010-01-11       Impact factor: 17.388

View more
  2 in total

1.  Leser-Trélat syndrome secondary to non-small-cell lung carcinoma.

Authors:  Rim Khemakhem; Nesrine Kallel; Rahma Jarraya; Ilhem Yangui; Samy Kammoun
Journal:  Clin Case Rep       Date:  2022-08-03

2.  A Case of Leser-Trélat Syndrome Associated with a Renal Cell Carcinoma.

Authors:  Dietrich Barth; Silvio Puhlmann; Joachim Barth
Journal:  Case Rep Dermatol       Date:  2015-09-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.